These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29623592)

  • 1. A Retrospective Cohort Study of Patients with Type 2 Diabetes in China: Associations of Hypoglycemia with Health Care Resource Utilization and Associated Costs.
    Yi Y; Li Y; Hou A; Ge Y; Xu Y; Xiong G; Yang X; Acevedo SA; Shi L; Xu H
    Diabetes Ther; 2018 Jun; 9(3):1073-1082. PubMed ID: 29623592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resource utilization and costs associated with using insulin therapy within a newly diagnosed type 2 diabetes mellitus population.
    Bell K; Parasuraman S; Raju A; Shah M; Graham J; Denno M
    J Manag Care Spec Pharm; 2015 Mar; 21(3):220-8a. PubMed ID: 25726031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health care resource utilization and cost of severe hypoglycemia treatment in insulin-treated patients with diabetes in the United States.
    Bajpai S; Wong-Jacobson S; Liu D; Mitchell B; Haynes G; Syring K; Ali AK; Chinthammit C
    J Manag Care Spec Pharm; 2021 Mar; 27(3):385-391. PubMed ID: 33645242
    [No Abstract]   [Full Text] [Related]  

  • 4. The Cost of Hypoglycemia Associated With Type 2 Diabetes Mellitus in Taiwan.
    Strizek A; Chang CJ; Furnback W; Wang B; Lebrec J; Lew T
    Value Health Reg Issues; 2019 May; 18():84-90. PubMed ID: 30776767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Burden of Hypoglycemia in Patients With Insulin-Treated Diabetes Mellitus in China: Analysis of Electronic Medical Records From 4 Tertiary Hospitals.
    Yue X; Wu J; Ruan Z; Wolden ML; Li L; Lin Y
    Value Health Reg Issues; 2020 May; 21():17-21. PubMed ID: 31634792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease.
    King A; Rajpura J; Liang Y; Paprocki Y; Uzoigwe C
    Curr Med Res Opin; 2022 Nov; 38(11):1831-1840. PubMed ID: 36134459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis.
    Eby EL; Wang P; Curtis BH; Xie J; Haldane DC; Idris I; Peters AL; Hood RC; Jackson JA
    J Med Econ; 2013; 16(4):529-38. PubMed ID: 23363330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare resource use, direct and indirect costs of hypoglycemia in type 1 and type 2 diabetes, and nationwide projections. Results of the HYPOS-1 study.
    Giorda CB; Rossi MC; Ozzello O; Gentile S; Aglialoro A; Chiambretti A; Baccetti F; Gentile FM; Romeo F; Lucisano G; Nicolucci A;
    Nutr Metab Cardiovasc Dis; 2017 Mar; 27(3):209-216. PubMed ID: 28017523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.
    Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L
    Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy.
    Raju A; Shetty S; Cai B; D'Souza AO
    J Manag Care Spec Pharm; 2016 May; 22(5):483-92. PubMed ID: 27123911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective analysis of medical costs and resource utilization for severe hypoglycemic events in patients with type 2 diabetes in Japan.
    Ikeda Y; Kubo T; Oda E; Abe M; Tokita S
    J Diabetes Investig; 2019 May; 10(3):857-865. PubMed ID: 30325576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus.
    Smolen HJ; Murphy DR; Gahn JC; Yu X; Curtis BH
    J Manag Care Spec Pharm; 2014 Sep; 20(9):968-84. PubMed ID: 25166296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
    Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
    J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
    [No Abstract]   [Full Text] [Related]  

  • 14. Insulin dosing and outcomes among commercially insured patients with type 2 diabetes in the United States.
    Eby EL; Van Brunt K; Brusko C; Curtis B; Lage MJ
    Clin Ther; 2015 Oct; 37(10):2297-2308.e1. PubMed ID: 26341171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Impact of Treatment Duration and Persistence with Basal Insulin in Previously Insulin-Naive Users.
    Kalirai S; Duan R; Liu D; Reed BL
    J Manag Care Spec Pharm; 2017 Mar; 23(3):327-336. PubMed ID: 28230446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
    Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
    Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare resource use and associated costs of hypoglycemia in patients with type 2 diabetes prescribed sulfonylureas.
    Alemayehu B; Liu J; Rajpathak S; Engel SS
    J Diabetes Complications; 2017 Nov; 31(11):1620-1623. PubMed ID: 28844830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic Control.
    Karkare S; Fridman M; Dang-Tan T; Lu J; Smolarz BG; DeKoven M; Iyer NN
    J Manag Care Spec Pharm; 2019 Jun; 25(6):658-668. PubMed ID: 30730232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
    Xie L; Wei W; Pan C; Baser O
    J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
    Bergeson JG; Worley K; Louder A; Ward M; Graham J
    J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.